KIDS V CANCER promotes pediatric cancer research by identifying structural impediments at key junctures in the research process – new drugs, tissue donation and access to funding – and developing strategies to address them.
Kids v Cancer won the Peter Drucker Prize for Most Innovative Nonprofit in 2015 and the Fast Company Top 10 most Innovative Nonprofits in 2016.
CREATING HOPE ACT, 21 U.S.C. 360ff
We authored and championed the Creating Hope Act Pediatric Priority Review Voucher Program, which was passed into law in 2012 as part of the 2012 FDA Safety and Innovation Act, 21 U.S.C. 360ff. The Creating Hope Act was reauthorized by Congress in 2016 as part of 21st Century Cures.
The Creating Hope Act provides a market-based incentive to spur pediatric cancer drug development in the form of pediatric priority review vouchers.
Under the Creating Hope Act, several vouchers have been awarded, including Unituxin for neuroblastoma. In 2015, a voucher sold for $350 million. Since 2012, about $1 billion in vouchers have been sold.
RACE FOR CHILDREN ACT (S 3239, HR 5858)
We authored the RACE for Children Act to update the Pediatric Research Equity Act (PREA) to help kids with cancer get access to the most promising therapies available. RACE for Children Act was introduced in the 114th Congress as HR 5858, S 3239.
The RACE for Children Act was endorsed in an editorial of Nature Magazine.
COMPASSIONATE USE NAVIGATOR
We assist physicians and families of children with cancer applying for compassionate use access to unapproved drugs.
ELIGIBILITY FOR ADULT TRIALS
Kids v Cancer is working with the FDA and NIH so that children and teens are included on adult cancer trials unless there is a scientific and ethical rationale not to.
AUTOPSY TISSUE DONATION PROGRAM
We have an autopsy tissue donation program to facilitate post mortem pediatric CNS tumor tissue to science.
Kids v Cancer successfully requested that September be declared as National Childhood Cancer Awareness Month for each year starting 2010.
Kids v Cancer is working with Imagine for Margo and a team of European regulators, industry, scientists and advocates to propose incentives for pediatric cancer drug development under European Union law.